Apr122020

Survey for Hodgkin Lymphoma Patients

IF YOU HAVE HODGKIN LYMPHOMA AND HAVE BEEN TREATED WITH THE FOLLOWING Therapy, YOU CAN HELP BY COMPLETING OUR SURVEY: 

Front-line treatment with brentuximab-vedotin (ADCETRIS) + chemotherapy

Lymphoma Canada is preparing a submission for the pan­Canadian Oncology Drug Review (pCODR) so that Hodgkin lymphoma patients in Canada can gain access to this therapy.

The survey results will provide us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS treatment IN CANADA.

The survey will be open until midnight Pacific Time on Sunday, April 12, 2020 and should only take 10 minutes of your time.

You may access the survey by clicking the link below:

Survey for Hodgkin lymphoma patients: Experience with brentuximab-vedotin (Adcetris) + chemotherapy

Like with Social Media